Page 34 - GTM-4-2

Global Translational Medicine Small RNA therapy for pancreatic cancer

3. Wang R, Lian J, Wang X, et al. Survival rate of colorectal 15. Sarvepalli D, Rashid MU, Rahman AU, et al. Gemcitabine:
cancer in China: A systematic review and meta-analysis. A review of chemoresistance in pancreatic cancer. Crit Rev
Front Oncol. 2023;13:1033154. Oncog. 2019;24(2):199-212.
doi: 10.3389/fonc.2023.1033154 doi: 10.1615/CritRevOncog.2019031641
4. Maleki Z, Vali M, Nikbakht HA, et al. Survival rate of 16. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus
ovarian cancer in Asian countries: A systematic review and gemcitabine for metastatic pancreatic cancer. New Engl J
meta-analysis. BMC Cancer. 2023;23(1):558. Med. 2011;364(19):1817-1825.
doi: 10.1186/s12885-023-11041-8 doi: 10.1056/NEJMoa1011923
5. Wang Z, Liu Z, Qu J, Sun Y, Zhou WJAMM. Role of natural 17. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F,
products in tumor therapy from basic research and clinical et al. Impact of FOLFIRINOX compared with gemcitabine
perspectives. Acta Mater Med. 2024;3:163-206. on quality of life in patients with metastatic pancreatic
cancer: Results from the PRODIGE 4/ACCORD 11
doi: 10.15212/AMM-2023-0050 randomized trial. J Clin Oncol. 2013;31(1):23-29.
6. Padillo-Ruiz J, Suarez G, Pereira S, et al. Circulating tumor doi: 10.1200/jco.2012.44.4869
cells enumeration from the portal vein for risk stratification
in early pancreatic cancer patients. Cancers (Basel). 18. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in
2021;13(24):6153. pancreatic cancer with nab-paclitaxel plus gemcitabine. New
Engl J Med. 2013;369(18):1691-1703.
doi: 10.3390/cancers13246153
doi: 10.1056/NEJMoa1304369
7. Bu LL, Yan J, Wang Z, et al. Advances in drug delivery for post-
surgical cancer treatment. Biomaterials. 2019;219:119182. 19. Hruban RH, Goggins M, Parsons J, Kern SE. Progression
model for pancreatic cancer. Clin Cancer Res. 2000;6(8):
doi: 10.1016/j.biomaterials.2019.04.027 2969-2972.
8. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted 20. Notta F, Chan-Seng-Yue M, Lemire M, et al. A renewed
therapeutics. Cell Metab. 2019;29(2):501. model of pancreatic cancer evolution based on genomic
doi: 10.1016/j.cmet.2019.01.001 rearrangement patterns. Nature. 2016;538(7625):378-382.
doi: 10.1038/nature19823
9. Yu AM, Choi YH, Tu MJ. RNA drugs AND RNA targets
for small molecules: Principles, progress, and challenges. 21. Corcoran RB, Contino G, Deshpande V, et al. STAT3 plays
Pharmacol Rev. 2020;72(4):862-898. a critical role in KRAS-induced pancreatic tumorigenesis.
Cancer Res. 2011;71(14):5020-5029.
doi: 10.1124/pr.120.019554
doi: 10.1158/0008-5472.Can-11-0908
10. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024.
CA Cancer J Clin. 2024;74(1):12-49. 22. Mello SS, Flowers BM, Mazur PK, et al. Multifaceted role for
p53 in pancreatic cancer suppression. Proc Natl Acad Sci U S
doi: 10.3322/caac.21820
A. 2023;120(10):e2211937120.
11. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman doi: 10.1073/pnas.2211937120
JM, Matrisian LM. Projecting cancer incidence and deaths to
2030: The unexpected burden of thyroid, liver, and pancreas 23. Doyle A, Kubler MM, Harris AC, et al. The impact of
cancers in the United States. Cancer Res. 2014;74(11): CDKN2A mutations on overall survival in pancreatic
2913-2921. adenocarcinoma. J Clin Oncol. 2019;37(4_suppl):278-278.
doi: 10.1158/0008-5472.Can-14-0155 doi: 10.1200/JCO.2019.37.4_suppl.278
12. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 24. Xia X, Wu W, Huang C, et al. SMAD4 and its role in
2023. CA A Cancer J Clin. 2023;73(1):17-48. pancreatic cancer. Tumour Biol. 2015;36(1):111-119.
doi: 10.3322/caac.21763 doi: 10.1007/s13277-014-2883-z
13. Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev 25. Xu Y, Lin Z, Ji Y, et al. Pan-cancer analysis identifies RNF43
Dis Primers. 2016;2(1):16022. as a prognostic, therapeutic and immunological biomarker.
Eur J Med Res. 2023;28(1):438.
doi: 10.1038/nrdp.2016.22
doi: 10.1186/s40001-023-01383-1
14. Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C,
Yang H. chemoresistance in pancreatic cancer. Int J Mol Sci. 26. Ishii N, Araki K, Yokobori T, et al. Reduced FBXW7
expression in pancreatic cancer correlates with poor
2019;20(18):4504.
prognosis and chemotherapeutic resistance via accumulation
doi: 10.3390/ijms20184504 of MCL1. Oncotarget. 2017;8(68):112636-112646.

Volume 4 Issue 2 (2025) 26 doi: 10.36922/gtm.8247